Pharmaron Holding

Pharmaron is a contract research, development, and manufacturing organization (CRDMO) that provides a comprehensive suite of services to the global life sciences industry. Founded in Beijing in 2004 by Dr. Boliang Lou, Larry Lou, and Bei Zheng, the company has grown from a specialized chemistry service provider into a fully integrated platform supporting the entire drug development lifecycle. Dr. Boliang Lou, the current Chairman and CEO, brought extensive experience from his time in the US pharmaceutical sector, having served as Director of Research at Advanced SynTech. His background in organic chemistry, with a Ph.D. from the Shanghai Institute of Organic Chemistry and post-doctoral research at the University of Montreal, has been instrumental in shaping the company's scientific direction.

The company operates a fee-for-service business model, generating revenue by offering its research and manufacturing capabilities to a diverse client base that includes pharmaceutical, biotechnology, and life sciences companies across North America, Europe, Japan, and China. Pharmaron's financial trajectory includes significant milestones such as its initial public offering on the Shenzhen Stock Exchange in January 2019, followed by a dual primary listing on the Hong Kong Stock Exchange in November 2019, which raised approximately HK$4.6 billion (US$588 million). This dual listing broadened the company's financing channels to support its global growth and expansion strategies.

Pharmaron's service portfolio is organized into four primary segments: laboratory services, Chemistry, Manufacturing, and Controls (CMC) services, clinical development services, and biologics & Cell and Gene Therapy (CGT) services. The laboratory services division, which is the largest revenue generator, encompasses discovery chemistry, biology, drug metabolism and pharmacokinetics (DMPK), and safety assessments. The company offers end-to-end support, from initial drug discovery and preclinical studies to clinical development and commercial manufacturing for various therapeutic modalities, including small molecules, biologics, and advanced CGT products. With operations in China, the U.S., and the U.K., and a workforce of over 21,000 employees, the company leverages its global footprint to provide integrated solutions aimed at accelerating the development of innovative medicines for its partners.

Keywords: drug development, contract research organization, life sciences, pharmaceutical services, CRDMO, clinical development, CMC services, biologics, cell and gene therapy, small molecules